Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisition by Celgene
Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s $9 billion
Name: Hans Bishop
Continent: North America
Country: USA
Company: Juno Therapeutics
Position: CEO
Reason: Resigned
Announcement Date: April 23, 2018, 10:00pm
Resignation Date: April 23, 2018, 10:00pm